The initial success of the copyright undeniably transformed the pharmaceutical landscape, but investing in companies primarily reliant on unbranded versions presents a uncertain picture. Although early returns were substantial, the expiration of patents and the appearance of cheaper alternatives have eroded the customer base. Therefore, a thorough